HRS 7053
Alternative Names: HRS-7053Latest Information Update: 21 Aug 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Aug 2023 Preclinical trials in Cancer in China (IV) prior to August 2023
- 09 Aug 2023 Jiangsu HengRui Medicine plans a phase I trial in Cancer (Late stage disease) (IV) in September 2023 (NCT05983146)